Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study

SIMPLE SUMMARY: In a double-blind, placebo-controlled, randomized phase 2 trial, Regorafenib provided a clinical benefit to patients with advanced and anthracycline-pretreated soft tissue sarcoma. However, extensive mutational analysis of tumor genes could not identify predictive markers of regorafe...

Descripción completa

Detalles Bibliográficos
Autores principales: Brodowicz, Thomas, Liegl-Atzwanger, Bernadette, Penel, Nicolas, Mir, Olivier, Blay, Jean-Yves, Kashofer, Karl, Le Cesne, Axel, Decoupigny, Emilie, Wallet, Jennifer, Hamacher, Rainer, Le Deley, Marie-Cecile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763753/
https://www.ncbi.nlm.nih.gov/pubmed/33322802
http://dx.doi.org/10.3390/cancers12123746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763753/
https://www.ncbi.nlm.nih.gov/pubmed/33322802
http://dx.doi.org/10.3390/cancers12123746

Ejemplares similares